Bris­tol-My­ers set to get a boost in Chi­na as Op­di­vo aces PhI­II lung can­cer study ear­ly

Bris­tol-My­ers Squibb ap­pears poised to win a big niche in Chi­na’s can­cer drug mar­ket. The com­pa­ny re­port­ed Thurs­day night that their Phase III com­par­ing their check­point in­hibitor Op­di­vo against do­c­etax­el — run pri­mar­i­ly in Chi­na — proved their ther­a­py was more ef­fec­tive in treat­ing sec­ond-line non-small cell lung can­cer pa­tients.

Bris­tol-My­ers $BMY is hold­ing on to the ac­tu­al da­ta on over­all sur­vival from Check­mate-078, but Chi­na’s FDA has the mar­ket­ing ap­pli­ca­tion un­der re­view. In­ves­ti­ga­tors re­cruit­ed 451 of 504 pa­tients in Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA